We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for real-time alerts, custom portfolio, and market movers
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| C4x Discovery Holdings Plc | LSE:C4XD | London | Ordinary Share | GB00BQQ2RV18 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 12.00 | 10.30 | 10.80 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 1.71M | -11.11M | -0.0441 | -2.72 | 30.27M |
From Oct 2023 to Apr 2024
By Ian Walker
C4X Discovery Holdings shares rose as much as 66% in early trade after the company said it has received a $11 million milestone payment from AstraZeneca.
Shares at 0846 GMT were up 3.76 pence, or 43%, at 12.50 pence having peaked at 14.50 pence earlier in the session. However, they are currently down 31% over the past 12 months.
The drug-discovery company said Wednesday that the payment was made under the licensing agreement with Astra under its inflammatory and respiratory disease NRF2 Activator program that was agreed in November 2022.
Under the program C4X could receive up to $400 million in milestone payments and future sales royalties.
"This significant preclinical milestone payment marks the progress AstraZeneca has made in driving the NRF2 Activator program forward... This is a great start to our year and we are confident of seeing further progress across our entire portfolio in 2024," C4X Chief Executive Clive Dix said.
Write to Ian Walker at ian.walker@wsj.com
(END) Dow Jones Newswires
January 03, 2024 04:10 ET (09:10 GMT)
Copyright (c) 2024 Dow Jones & Company, Inc.
1 Year C4x Discovery Chart |
1 Month C4x Discovery Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
